Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients
Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The ReBIC-1 trial was designed to evaluate the potential clinical risks and benefits of
withdrawing furosemide use in stable, apparently euvolemic, chronic HF outpatients in a
multicentric double-blinded randomized clinical trial.
Phase:
Phase 3
Details
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Collaborator:
Conselho Nacional de Desenvolvimento Científico e Tecnológico